282 related articles for article (PubMed ID: 30536539)
1. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
2. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
Yao Y; Findlay A; Stolp J; Rayner B; Ask K; Jarolimek W
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628342
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.
Klepfish M; Gross T; Vugman M; Afratis NA; Havusha-Laufer S; Brazowski E; Solomonov I; Varol C; Sagi I
Front Immunol; 2020; 11():480. PubMed ID: 32296422
[TBL] [Abstract][Full Text] [Related]
4. Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
Findlay AD; Foot JS; Buson A; Deodhar M; Jarnicki AG; Hansbro PM; Liu G; Schilter H; Turner CI; Zhou W; Jarolimek W
J Med Chem; 2019 Nov; 62(21):9874-9889. PubMed ID: 31580073
[TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy.
Stangenberg S; Saad S; Schilter HC; Zaky A; Gill A; Pollock CA; Wong MG
Sci Rep; 2018 Jun; 8(1):9423. PubMed ID: 29930330
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
Ikenaga N; Peng ZW; Vaid KA; Liu SB; Yoshida S; Sverdlov DY; Mikels-Vigdal A; Smith V; Schuppan D; Popov YV
Gut; 2017 Sep; 66(9):1697-1708. PubMed ID: 28073888
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.
Nguyen LT; Saad S; Shi Y; Wang R; Chou ASY; Gill A; Yao Y; Jarolimek W; Pollock CA
Sci Rep; 2021 Jun; 11(1):12437. PubMed ID: 34127702
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
10. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
Rowbottom MW; Bain G; Calderon I; Lasof T; Lonergan D; Lai A; Huang F; Darlington J; Prodanovich P; Santini AM; King CD; Goulet L; Shannon KE; Ma GL; Nguyen K; MacKenna DA; Evans JF; Hutchinson JH
J Med Chem; 2017 May; 60(10):4403-4423. PubMed ID: 28471663
[TBL] [Abstract][Full Text] [Related]
11. Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.
Jones MG; Andriotis OG; Roberts JJ; Lunn K; Tear VJ; Cao L; Ask K; Smart DE; Bonfanti A; Johnson P; Alzetani A; Conforti F; Doherty R; Lai CY; Johnson B; Bourdakos KN; Fletcher SV; Marshall BG; Jogai S; Brereton CJ; Chee SJ; Ottensmeier CH; Sime P; Gauldie J; Kolb M; Mahajan S; Fabre A; Bhaskar A; Jarolimek W; Richeldi L; O'Reilly KM; Monk PD; Thurner PJ; Davies DE
Elife; 2018 Jul; 7():. PubMed ID: 29966587
[TBL] [Abstract][Full Text] [Related]
12. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
13. Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin.
Schmelzer CEH; Heinz A; Troilo H; Lockhart-Cairns MP; Jowitt TA; Marchand MF; Bidault L; Bignon M; Hedtke T; Barret A; McConnell JC; Sherratt MJ; Germain S; Hulmes DJS; Baldock C; Muller L
FASEB J; 2019 Apr; 33(4):5468-5481. PubMed ID: 30676771
[TBL] [Abstract][Full Text] [Related]
14. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W; Yang A; Jia J; Popov YV; Schuppan D; You H
Hepatology; 2020 Aug; 72(2):729-741. PubMed ID: 32176358
[TBL] [Abstract][Full Text] [Related]
15. LOXL3 Function Beyond Amino Oxidase and Role in Pathologies, Including Cancer.
Laurentino TS; Soares RDS; Marie SKN; Oba-Shinjo SM
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340433
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic processing of lysyl oxidase-like-2 in the extracellular matrix is required for crosslinking of basement membrane collagen IV.
López-Jiménez AJ; Basak T; Vanacore RM
J Biol Chem; 2017 Oct; 292(41):16970-16982. PubMed ID: 28864775
[TBL] [Abstract][Full Text] [Related]
17. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin.
Kim YM; Kim EC; Kim Y
Mol Biol Rep; 2011 Jan; 38(1):145-9. PubMed ID: 20306300
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking.
Zhao W; Yang A; Chen W; Wang P; Liu T; Cong M; Xu A; Yan X; Jia J; You H
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1129-1137. PubMed ID: 29366776
[TBL] [Abstract][Full Text] [Related]
19. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
20. LOX/LOXL in pulmonary fibrosis: potential therapeutic targets.
Chen L; Li S; Li W
J Drug Target; 2019 Aug; 27(7):790-796. PubMed ID: 30457362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
